trending Market Intelligence /marketintelligence/en/news-insights/trending/y49adkmq53xh4ntqw-pyvq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

La Jolla enters $125M financing deal for blood pressure drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

La Jolla enters $125M financing deal for blood pressure drug

La Jolla Pharmaceutical Company entered a $125 million royalty financing deal with private equity firm HealthCare Royalty Partners to commercialize its blood pressure drug Giapreza.

Under the agreement, the San Diego-based biopharmaceutical company will receive $125 million in exchange for tiered royalty payments on worldwide net sales of Giapreza. The payment obligations will expire once reaching the threshold limit of 180% of the $125 million.

La Jolla said adjusting for the net proceeds from the transaction, the company's cash and cash equivalents as of March 31 were $279 million.

The U.S. Food and Drug Administration approved Giapreza in December 2017. The medicine helps to increase blood pressure in adults who experience abnormal distribution of blood flow in blood vessels resulting in inadequate supply to the body's tissues and organs — known as distributive shock.

La Jolla President and CEO George Tidmarsh said the transaction will provide the company with a "strong financial position" to support the commercial launch of Giapreza and development of other product candidates.